Hitting a Wegovy Plateau: Why It Happens and What to Do

A plateau is when your weight stops decreasing despite continued treatment. On semaglutide, the average plateau begins around week 60 of treatment, per the STEP 1 trial — coinciding with about 15% of starting weight lost. On tirzepatide, plateaus tend to occur a bit later, around week 72, at approximately 20% lost. This is not a sign the medication has stopped working; it's your body reaching a new energy-balance equilibrium. The remarkable thing about GLP-1s is not that they prevent plateaus — they don't — but that they push the plateau to a much lower body weight than diet alone.

Three coordinated mechanisms drive plateaus. First, basal metabolic rate falls: a 2016 study of *Biggest Loser* contestants showed RMR was about 500 kcal/day lower than predicted six years after weight loss, even adjusting for new body weight. Second, hunger hormones rebound: ghrelin rises and leptin falls, increasing appetite — though GLP-1s blunt this somewhat. Third, non-exercise activity thermogenesis (NEAT) drops: you fidget less, walk slightly less, and stand less, sometimes burning 100–300 fewer kcal per day without noticing. The body is defending its 'set point,' and at lower body weights this defense intensifies.

First, check the timeframe: the scale routinely fluctuates 1–4 lb day to day with hydration, sodium, sleep, and (for menstruating people) cycle phase. A real plateau means no net loss for 4+ weeks at consistent weighing conditions. Second, check measurements: many people lose inches without losing pounds during recomposition — chest, waist, hips, and thighs may shrink while muscle mass climbs. Third, check progress photos and how clothes fit. If all three measures are flat for a month, it's a true plateau. If you're losing inches or feeling clothes get loose, you are still progressing.

Five evidence-based interventions work for most people. (1) Increase protein to 0.7–1.0 g per pound of goal body weight — this preserves lean mass and increases the thermic effect of food. (2) Add or intensify resistance training 2–4 times weekly. SURMOUNT and STEP subgroup analyses show resistance training preserves more muscle than cardio alone. (3) Audit calories. Many people unconsciously add 200–400 kcal daily as the early appetite suppression wears off; track honestly for 3 days. (4) Increase steps. Aim for 8,000–10,000 daily; NEAT compensation can erase deficit. (5) Optimize sleep: less than 6 hours nightly raises ghrelin and reduces fat loss. Try one intervention at a time for 4 weeks before adding another.

Talk to your provider. Options include going to maximum dose (semaglutide 2.4 mg or tirzepatide 15 mg) if you aren't there yet, switching from semaglutide to tirzepatide which often breaks plateaus given tirzepatide's higher average efficacy in SURMOUNT-5, or adding a complementary medication like bupropion-naltrexone in carefully selected patients. Some clinicians use a brief drug holiday and re-titration, though there's limited trial evidence for this strategy. Avoid the temptation to skip doses or self-adjust — irregular dosing tends to worsen plateaus by causing rebound hunger.

Sometimes the body has reached a healthy, sustainable weight that it's well-defended at. If you're in a normal BMI range, your labs (A1c, lipids, blood pressure) have improved, your strength is up, and your quality of life is better — that may be your maintenance weight. Not every plateau needs breaking. The goal of GLP-1 therapy is improved metabolic health, not a specific scale number. Many obesity specialists now favor a 'weight reduction of 10–15% sustained' as the meaningful clinical target rather than continued chasing of a number. Discuss with your provider whether to push further or shift to long-term maintenance.